Global Orthobiologics Market is anticipated to witness a CAGR of 7% by 2026 - An Increasing number of patients suffering from Arthritis and other Spine Disorders

Orthobiologics employ biomaterials and cell-based therapies to quickly heal musculoskeletal injuries and support tissue healing and restoration through their regenerative potential. These products are derived from components which are naturally present in the body and interact dynamically with the musculoskeletal system to facilitate the quick healing of bone, cartilage, ligament, and diseased or injured meniscus & tendons.

Rapid Technological Innovations in the Global Orthobiologics Market

Consistent innovations and developments in orthobiologics have enabled to develop efficient market products with advanced healing capabilities and growing applications, among others. Such innovations tend to provide a competitive edge to all manufacturers and hence, all top players are focusing on investing in their research activities for new product development and growing their geographic reach to strengthen their position in the global orthobiologics market.

Some of the technological innovations and developments are listed below:
• In June 2022, Istos Biologics launched the Influx Fibrant line of 100% cortical allograft products featuring a patented technology from TheraCell and designed to advance patient healing.
• In March 2022, SeaSpine launched new orthobiologic products- NorthStar cervical facet fusion and Flash navigation lumbar facet fusion, with an aim to streamline reproducible procedural workflow while maximizing the area for fusion.

Aggressive Growth Strategies Adopted by the Established Market Players in the Global Orthobiologics Market

All leading market players operating in the global orthobiologics market have adopted collaborations, acquisitions and partnerships as a key growth strategy to expand their product offerings, improve their geographic reach and to co-develop advanced market products.

Irrespective of the upcoming market challenges such as unfavorable reimbursement scenario and increasing pricing pressure on leading market players, the global orthobiologics market is growing strong and is set to gain a consistent momentum in the upcoming years due to a primary focus on spinal fusion segment, focus on demineralized bone putties with excipients, growing usage of viscosupplements, and advancements addressing the whole procedures.

For instance, during the forecast period, the viscosupplements segment is poised to be driven by innovations in hyaluronic acid-based therapies, growing cases of lifestyle-induced disorders, high effectiveness in delaying total knee replacement procedures, and rising preference for non-surgical treatments for osteoarthritis.

Further, traditionally techniques such as autograft and allograft are tough to manage, painful for the patients, have contrasting results, and may need repeat surgeries. Hence, an easier-to-use solution is likely to be accepted by doctors and healthcare providers which has a greater success rate from a medical and financial standpoint, providing ample opportunities for the market players operating in this segment.

Competitive Landscape Analysis: Global Orthobiologics Market

The global orthobiologics market is marked by the presence of well-established and leading market players such as Medtronic Plc (Ireland); Zimmer Biomet Holdings, Inc. (US); Arthrex, Inc. (US); Bioventus (US); DePuy Synthes (Johnson & Johnson Services, Inc.) (US); Stryker Corporation (US); MTF Biologics (US).

Explore More Detailed Insights on Orthobiologics Market with a Sample Copy @ https://meditechinsights.com/orthobiologics-market/

Ruta Halde
Associate, Medi-Tech Insights
121/7E Avenue Franklin Roosevelt,
1050 Brussels, Belgium
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.